Latest Inhaler Stories
Meet the Next Generation of Monitored Medication Dispensers Pittsburgh, PA (PRWEB) April 04, 2012 In a world where technology keeps making everything easier, Pittsburgh-based Automated Security Alert is offering some new products to make life easier for people with chronic health problems. One of the company’s newest offerings is the Dispense-A-Pill, a sophisticated but easy-to-use electronic pill dispenser. Although the company has different monitored medication dispensers to choose...
Under Economic Strain, More Women Rely on Community Health Centers for their Daily Health Needs SANTA BARBARA, Calif., April 3, 2012 /PRNewswire-USNewswire/ -- In an effort to provide better care to uninsured women across the country, Teva Pharmaceuticals has provided Direct Relief USA with a donation of women's health products valued at $3 million (wholesale). The donation of 5,000 units of ParaGard®, an intrauterine copper contraceptive, will be distributed by Direct Relief to the...
REDWOOD CITY, Calif., April 3, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced that the company has successfully formulated and manufactured metered-dose inhalers (MDI) that deliver 300ng per actuation of glycopyrrolate (GP), a highly potent, long-acting muscarinic antagonist (LAMA) using its porous particle cosuspension technology. By breaking the microgram dose barrier, Pearl aims to evaluate completely the safety and efficacy profiles of GP, and other very potent...
REDWOOD CITY, Calif., Jan. 6, 2012 /PRNewswire/ -- Pearl Therapeutics Inc. today announced the completion of two Phase 2b clinical studies of PT003, the Company's investigational inhaled combination bronchodilator product for the treatment of patients with moderate-to-severe COPD. The first of these two trials (NCT01349803) was a 237-subject cardiovascular safety study designed to measure the change in mean heart rate following twice-daily (BID) chronic administration of the...
SAN DIEGO, Jan. 4, 2012 /PRNewswire/ -- Elevation Pharmaceuticals, Inc. announced today the closing of a $30 million Series B financing, led by new investor Novo Ventures, to fund development of Elevation's new aerosol therapy for patients living with chronic obstructive pulmonary disease (COPD). All previous investors participated in the round, including Canaan Partners, TPG Biotech, Care Capital and Mesa Verde Venture Partners. In conjunction with this financing, Elevation has...
EXTON, Pa., Jan. 3, 2012 /PRNewswire/ -- Pharmaxis, Inc. today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific billing code, or J-code, for ARIDOL® (mannitol inhalation powder) Bronchial Challenge Test Kit. The unique, product-specific billing code, J7665 (mannitol, administered through an inhaler, 5 mg), became effective on January 1, 2012. (Photo: http://photos.prnewswire.com/prnh/20111107/NY00591 ) ARIDOL, the only dry...
(Ivanhoe Newswire) – Adding inhaled powder mannitol to standard therapy for cystic fibrosis produced consistent lung function improvement for up to 52 weeks, according to this study. Mannitol treatment is not only efficient and safe, but it’s easy to administer as well. In the double-blind study, which was supported by Pharmaxis Limited, 318 patients were randomized to treatment with 400 mg bid inhaled mannitol or 50 mg bid inhaled mannitol (control group) for 26 weeks, followed by an...
DUSSELDORF, Germany, December 19, 2011 /PRNewswire/ -- - Growth in demand for pharmaceutical and medical plastic systems - Gerresheimer invests around EUR 25 million in its Pfreimd plant - 130 new jobs Gerresheimer AG, one of the world's leading suppliers to the pharma and healthcare industry, further invests in the growth market of complex plastic systems for pharmaceutical and medical applications. Production capacity is being...
Adding inhaled dry powder mannitol to standard therapy for cystic fibrosis produced sustained improvement in lung function for up to 52 weeks, according to a new study. Along with the treatment's efficacy and good safety profile, the convenience and ease of administration of mannitol treatment may improve adherence with therapy in these patients. In the double-blind study, which was supported by Pharmaxis Limited, 318 patients were randomized to treatment with 400 mg bid inhaled mannitol...
REDWOOD CITY, Calif., Dec. 7, 2011 /PRNewswire/ -- Pearl Therapeutics Inc. today announced positive top-line results from a randomized, double-blind, Phase 2b, dose-ranging study of glycopyrrolate, a long-acting muscarinic agonist (LAMA) delivered twice a day (BID) via metered-dose inhaler (GP MDI; PT001) in patients with moderate-to-severe COPD. Four doses of GP MDI were compared to placebo and Atrovent® HFA Inhalation Aerosol, a short-acting muscarinic antagonist given...
